(Q40553648)

English

Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy

scientific article published on August 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

1 reference

based on heuristic

inferred from title

author name string

van der Kolk LE

1

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Grillo-López AJ

2

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Baars JW

3

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

van Oers MH

4

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

publication date

1 August 2003

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

1658-1664

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

https://scigraph.springernature.com/pub.10.1038/sj.leu.2402995

0 references

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402995

21 January 2018

Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402995

21 January 2018

Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402995

21 January 2018

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402995

21 January 2018

Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402995

21 January 2018

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402995

21 January 2018

Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402995

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402995

7 January 2021

based on heuristic

inferred from DOI database lookup

Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402995

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402995

7 January 2021

based on heuristic

inferred from DOI database lookup

Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402995

7 January 2021

based on heuristic

inferred from DOI database lookup

Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402995

7 January 2021

based on heuristic

inferred from DOI database lookup

A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402995

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402995

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of in vivo administration of G-CSF on neutrophil functions in healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402995

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2402995

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40553648&oldid=1900289430"